Baxter launches sevoflurane in China

Baxter Healthcare says it has launched sevoflurane, the world's most widely-used inhaled anesthetic, in China. The company also unveiled its plans for a phased introduction of sevoflurane in additional geographies throughout 2006, including the USA, Japan and, on regulatory approval, certain European markets.

Baxter says its sevoflurane is chemically and therapeutically equivalent to Abbott Laboratories' Ultane. The addition of sevoflurane distinguishes Baxter as the only company that offers all three modern inhaled anesthetics globally - sevoflurane, Suprane (desflurane, USP) and Forane (isoflurane, USP). In addition, Baxter offers the intravenous anesthetic, propofol, in the USA.

"With the addition of sevoflurane, Baxter now provides the broadest portfolio of inhaled anesthetics to its customers worldwide," said Daniel Tasse, general manager of Anesthesia, Critical Care and Oncology, part of the group's Medication Delivery business. "We will leverage our strong customer relationships and channels, along with investments we've made in sales and marketing, to successfully launch sevoflurane," he added.